SMALL GRANTS FOR THERAPEUTIC CLINICAL TRIALS OF MALIGNANCIES NIH GUIDE, Volume 23, Number 10, March 11, 1994 PAR NUMBER: PAR-94-048 P.T. 34 Keywords: Chemotherapy Radiotherapy Surgery National Cancer Institute Application Receipt Dates: June 1, October 1, February 1 PURPOSE The Division of Cancer Treatment (DCT), National Cancer Institute (NCI) announces a program to encourage the submission of small grant applications for new pilot, phase I, or phase II therapeutic clinical trials of malignancies that take advantage of recent laboratory developments. New and experienced investigators in relevant fields and disciplines (clinical, surgical, and radiation oncology) may apply for small grants to test new treatment strategies or do pilot studies. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Small Grants for Therapeutic Clinical Trials, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State or local governments, and eligible agencies of the Federal government. Applications may be from a single institution or several institutions (collaborating institutions, consortia, clinical trials cooperative groups), if appropriate. New and experienced investigators are encouraged to apply. Applications from minority and women individuals encouraged. MECHANISM OF SUPPORT Support of the program will be through the National Institutes of Health (NIH) small grants (R03) mechanism. The small grants research program provides limited funds (maximum of $50,000 direct costs per year) for short-term (up to two years) research projects. These grants are non-renewable and continuation of projects developed under this program will be through the regular grant program. Applicants will be responsible for the planning, direction, and execution of the proposed project. Applications submitted in response to this Program Announcement (PA) will compete for funds with all other R03 grant applications assigned to the NCI. The award of grants in response to this PA is also contingent upon the availability of funds. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH) 90-50,000, revised October 1, 1990. RESEARCH OBJECTIVES Background The NCI supports an extensive network of clinical and laboratory research studies related to cancer therapy through contracts, grants, and cooperative agreements. At present, there is no mechanism targeted to stimulate the communication of promising and potentially relevant new developments between the laboratory and the clinical setting. There is a need for a mechanism to fund short-term studies and obtain preliminary clinical data rapidly. It is expected that these R03 grants will serve as a basis for planning future clinical research grant applications (R01) or NCI cooperative clinical trial group studies. The small grants (R03) mechanism provides research support specifically limited in time and amount for studies in categorical program areas (see Research Goals and Scope). Small grants provide flexibility for initiating preliminary, short-term studies and are non-renewable. Furthermore, the time interval from application to funding is shortened under the R03 mechanism, thus allowing new ideas to be investigated or pursued in a more expeditious manner. The Cancer Therapy Evaluation Program, DCT, NCI has targeted the use of the small grants mechanism to support single or several institutions to perform therapeutic clinical trials to test new ideas. Support is needed to encourage new as well as experienced investigators to apply new treatment approaches. Research Goals and Scope The aim of this initiative is to support pilot, phase I, or phase II therapeutic clinical trials of malignancies to move new treatment strategies more rapidly from the laboratory into the clinic. Clinical studies must involve human subjects and be therapeutic in design. The clinical studies must be based on a strong rationale and preclinical data should support the underlying hypotheses. The research plan should be focused on the clinical trial proposed. New clinical therapeutic trials employing drugs, biologics, radiation, or surgery whether used as a single agent/modality or in combination are appropriate. Laboratory studies may also be proposed to conduct pharmacokinetic, pharmacodynamic, and other important correlative studies in the cancer patients receiving therapy. The laboratory studies should be in support of the clinical trial, such that their conduct leads to a greater understanding of the relationship between drug administration and biological changes in patients. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator must be included with the application. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES NIH policy is that applicants for NIH clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign consortium participants, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91). Applications must be received by the following receipt dates: June 1, October 1, and February 1 of 1994 and 1995. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/710-0267. The title and number of this Program Announcement must be typed in line 2a on the face page of the application. Submit a signed, typewritten original of the application, including the Checklist, and four signed, exact photocopies, in one package: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, one additional copy of the application must also be sent to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Room 636A 6130 Executive Boulevard Bethesda, MD 20892 The application must meet the requirements listed below. The Research Plan of the application is limited to 16 pages total. A suggested page limitation is as follows: o Specific Aims - one page o Background, Significance, and Preliminary Studies - five pages o Research Design and Methods - 10 pages Following the research plan, include the discussion of Human Subjects and the literature cited. Human subjects approval and IRB approval of clinical protocols must be obtained prior to review. Documentation for the composition of the proposed study population in terms of gender and racial/ethnic group together with a rationale for its choice must be included in the Human Subjects section. The clinical protocol must be included in the Appendix. REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit by an appropriate review group at the Division of Extramural Activities, National Cancer Institute. Foreign grant applications will also be reviewed by the National Cancer Advisory Board. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned to the NCI. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Ms. Diane Bronzert or Dr. Roy Wu Division of Cancer Treatment National Cancer Institute Executive Plaza North, Room 734 Bethesda, MD 20892 Telephone: (301) 496-8866 FAX: (301) 480-4663 Direct inquiries regarding fiscal matters to: Ms. Eileen Natoli Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 56 FAX: (301) 496-8601 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No 93.395, Cancer Treatment Research. Awards are made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended, Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |